Intersect ENT Inc (NASDAQ:XENT) was the target of some unusual options trading on Thursday. Traders acquired 2,233 call options on the stock. This is an increase of 834% compared to the average daily volume of 239 call options.

NASDAQ:XENT traded up $0.87 during midday trading on Friday, hitting $29.63. 2,452 shares of the stock were exchanged, compared to its average volume of 703,437. Intersect ENT has a one year low of $14.61 and a one year high of $35.87. The company has a market capitalization of $852.48 million, a price-to-earnings ratio of -23.09 and a beta of 0.91. The business has a 50-day moving average price of $25.24 and a two-hundred day moving average price of $20.40.

Institutional investors have recently bought and sold shares of the company. Quadrant Capital Group LLC acquired a new stake in shares of Intersect ENT in the 3rd quarter valued at $36,000. Great West Life Assurance Co. Can acquired a new position in shares of Intersect ENT during the fourth quarter valued at about $52,000. Meeder Asset Management Inc. increased its stake in Intersect ENT by 311.8% in the fourth quarter. Meeder Asset Management Inc. now owns 3,694 shares of the medical equipment provider’s stock valued at $91,000 after acquiring an additional 2,797 shares during the period. Bank of Montreal Can increased its stake in Intersect ENT by 42.5% in the fourth quarter. Bank of Montreal Can now owns 3,838 shares of the medical equipment provider’s stock valued at $96,000 after acquiring an additional 1,144 shares during the period. Finally, Victory Capital Management Inc. increased its stake in Intersect ENT by 36.9% in the fourth quarter. Victory Capital Management Inc. now owns 6,778 shares of the medical equipment provider’s stock valued at $169,000 after acquiring an additional 1,827 shares during the period. Institutional investors and hedge funds own 96.87% of the company’s stock.

XENT has been the subject of several research reports. Piper Jaffray Companies set a $21.00 target price on Intersect ENT and gave the company a “hold” rating in a report on Friday, November 1st. JPMorgan Chase & Co. increased their target price on Intersect ENT from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Finally, BidaskClub upgraded Intersect ENT from a “hold” rating to a “buy” rating in a report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $27.25.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Recommended Story: What is the Nikkei 225 index?    

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.